From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development
Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…
Certara2026 年 4 月 28 日
ADC Dose Optimization: Applying Model-Informed Strategies in Development
Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…
Certara2026 年 4 月 22 日
Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body
JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 4 月 16 日 When I first began learning about pharmacokinetics (PK), I was often…
Certara2026 年 4 月 16 日
PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)
Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…
Certara2026 年 4 月 9 日
Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations
Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…
Certara2026 年 4 月 2 日
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
This study demonstrates how a model-informed, totality-of-evidence approach was used to select the optimal clinical…
Danielle Pillsbury2026 年 4 月 2 日
Where Did the 80-125% Bioequivalence Criteria Come From?
Discover what bioequivalence criteria mean, why the 80-125% bioequivalence range is used, and how custom…
Certara2026 年 3 月 27 日
Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection
PK/PD Modeling for CNS drug development using Phoenix NLME and machine learning for better CNS…
Certara2026 年 3 月 26 日
